Oleic acid increases uptake and decreases the P-gp-mediated efflux of the veterinary anthelmintic Ivermectin

Abstract

The bioavailability of ivermectin is modulated by lipid-based formulations and membrane efflux transporters such as Breast Cancer Resistance Protein and P-glycoprotein (BCRP and P-gp). We have investigated the effect of oleic acid on the uptake of ivermectin in vitro using Caco-2 cells and in vivo in the intestines of wild-type mice. Complex micelles (M) with oleic acid induced a significant increase (e. g. for M3 was 7-fold, p≤0.001) in the uptake of the drug in a time-dependent manner with no involvement of cholesterol in the mechanism. In vivo results showed a significant increase in the concentration of plasma and intestinal mucosa ivermectin (p≤0.01) in mice receiving oleic acid-based drug formulation. We also examined the expression of the drug efflux transporter, BCRP and P-gp in Caco-2 cells and found a significant decrease (p≤0.001) in their level in the presence of 5 mM oleic acid. Treatment of mice with oleic acid-based formulation showed a significant decrease in the activity of P-gp in the intestinal mucosa (p≤0.01). This study highlighted the effect of oleic acid in decreasing the expression and the activity of P-gp-mediated ivermectin efflux and in limiting the drug absorption by increasing its uptake and bioavailability in Caco-2 cells and intestine, respectively.

Key words

Oleic acid - ivermectin - P-glycoprotein - BCRP

^* These authors contributed equally to the paper

• References

• 1 Camargo JA, Sapin A, Daloz D. et al. Ivermectin-loaded microparticles for parenteral sustained release: In vitro characterization and effect of some formulation variables. J Microencapsul 2010; 27: 609-617
• 2 Lespine A. Lipid-like properties and pharmacology of the anthelmintic macroyclic lactones. Expert Opin Drug Metab Toxicol 2013; 9: 1581-1595
• 3 Lespine A, Dupuy J, Alvinerie M. et al. Interaction of macrocyclic lactones with the multidrug transporters: The bases of the pharmacokinetics of lipid-like drugs. Curr Drug Metab 2009; 10: 272-288
• 4 Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 6: 231-248
• 5 Cotreau MM, Warren S, Ryan JL. et al. The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol 2003; 43: 1108-1115
• 6 Bassissi MF, Alvinerie M, Lespine A. Macrocyclic lactones: Distribution in plasma lipoproteins of several animal species including humans. Comp Biochem Physiol C Toxicol Pharmacol 2004; 138: 437-444
• 7 Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340-7358
• 8 Lespine A, Menez C, Bourguinat C. et al. P-glycoproteins and other ABC transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resistance 2012; 2: 58-75
• 9 Didier A, Loor F. The abamectin derivative ivermectin is a potent Pglycoprotein inhibitor. Anticancer Drugs 1996; 7: 745-751
• 10 Griffin J, Fletcher N, Clemence R. et al. Selamectin is a potent substrate and inhibitor of human and canine P-gp. J Vet Pharmacol Ther 2005; 28: 257-265
• 11 Schinkel AH, Smit JJ, van Tellingen O. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502
• 12 Hennessy DR, Alvinerie MR. Pharmacocinetics of the macrocyclic lactones: Conventional wisdom and new paradigms. New York: CAB International; 2002
• 13 Kiki-Mvouaka S, Menez C, Borin C. et al. Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug Metab Dispos 2010; 38: 573-580
• 14 Lifschitz A, Suarez VH, Sallovitz J. et al. Cattle nematodes resistant to macrocyclic lactones: Comparative effects of P-glycoprotein modulation on the efficacy and disposition kinetics of ivermectin and moxidectin. Exp Parasitol 2010; 125: 172-178
• 15 Mealey KL. ABCG2 transporter: Therapeutic and physiologic implications in veterinary species. J Vet Pharmacol Ther 2012; 35: 105-112
• 16 Chateau D, Pauquai T, Delers F. et al. Lipid micelles stimulate the secretion of triglyceride-enriched apolipoprotein B48-containing lipoproteins by Caco-2 cells. J Cell Physiol 2005; 202: 767-776
• 17 Reboul E, Abou L, Mikail C. et al. Lutein transport by Caco-2 TC-7 cells occurs partly by a facilitated process involving the scavenger receptor class B type I. Biochem J 2005; 387: 455-461
• 18 Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
• 19 Alvinerie M, Escudero E, Sutra JF. et al. The pharmacokinetics of moxidectin after oral and subcutaneous administration to sheep. Vet Res 1998; 29: 113-118
• 20 Vuguin PM, Kedees MH, Cui L. et al. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology. 2006; 147: 3995-4006
• 21 Li M, Si L, Pan H. et al. Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: Assessed in vitro by everted gut sac and in situ by improved intestinal perfusion. Int J Pharm 2011; 403: 37-45
• 22 Li L, Yi T, Lam CW. Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS). Int J Pharm 2013; 447: 192-198
• 23 Brocks DR, Wasan KM. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. J Pharm Sci 2002; 91: 1817-1826
• 24 Shayeganpour A, Jun AS, Brocks DR. Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 2005; 26: 249-257
• 25 Guzzo CA, Furtek CI, Porras AG. et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002; 42: 1122-1133
• 26 Lespine A, Chanoit G, Bousquet-Melou A. et al. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs. Eur J Pharm Sci 2006; 27: 37-43
• 27 Prichard R, Ménez C, Lespine A. Moxidectin and the avermectins: Consanguinity but not identity. Int J Parasitol Drugs Drug Resist 2012; 14: 134-153
• 28 Nanjwade BK, Patel DJ, Udhani RA. et al. Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs. Sci Pharm 2011; 79: 705-727
• 29 Miyajima A, Hirota T, Sugioka A. et al. Effect of high-fat meal intake on the pharmacokinetic profile of ivermectin in Japanese patients with scabies. J Dermatol 2016; 43: 1030-1036
• 30 Van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol 2005; 1: 175-185
• 31 Tsuzuki W. Absorption properties of micellar lipid metabolites into Caco-2 cells. Lipids 2007; 42: 613-619
• 32 Qua DQ, Xu GX. Formulation optimization of self-emulsifying preparations of puerarin through self-emulsifying performances evaluation in vitro and pharmacokinetic studies in vivo. Yao Xue Xue Bao 2007; 42: 886-891
• 33 Ménez C, Mselli-Lakhal L, Foucaud-Vignault M. et al. Ivermectin induces P-glycoprotein expression and function through mRNA stabilization in murine hepatocyte cell line. Biochem Pharmacol 2012; 83: 269-278
• 34 Aspenström-Fagerlund B, Tallkvist J, Ilbäck NG. et al. Oleic acid decreases BCRP mediated efflux of mitoxantrone in Caco-2 cell monolayers. Food Chem Toxicol 2012; 50: 3635-3645